14-3-3 Sigma Interacts with Liver X Receptor Beta Emily Ann Jackson Louisiana State University and Agricultural and Mechanical College, [email protected]

Total Page:16

File Type:pdf, Size:1020Kb

14-3-3 Sigma Interacts with Liver X Receptor Beta Emily Ann Jackson Louisiana State University and Agricultural and Mechanical College, Ejacks5@Tigers.Lsu.Edu Louisiana State University LSU Digital Commons LSU Master's Theses Graduate School 2010 14-3-3 sigma interacts with liver X receptor beta Emily Ann Jackson Louisiana State University and Agricultural and Mechanical College, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses Recommended Citation Jackson, Emily Ann, "14-3-3 sigma interacts with liver X receptor beta" (2010). LSU Master's Theses. 4251. https://digitalcommons.lsu.edu/gradschool_theses/4251 This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Master's Theses by an authorized graduate school editor of LSU Digital Commons. For more information, please contact [email protected]. 14-3-3 SIGMA INTERACTS WITH LIVER X RECEPTOR BETA A Thesis Submitted to the Graduate Faculty of the Louisiana State University and Agricultural and Mechanical College in partial fulfillment of the requirements for the degree of Master of Science in The Department of Biological Sciences by Emily Ann Jackson B.S., Louisiana State University, 2004 May 2010 ACKNOWLEDGEMENTS I would like to thank God for blessing me with the strength, knowledge, and patience to get me through this journey. I would like to acknowledge my family, Brenda W. Jackson, for praying for me and instilling the morals and values necessary for me to succeed in life, my sister and niece, Earmer M. Jackson and Jeanette E. Jackson, for being very supportive throughout my life. Also, I would like to acknowledge my family and friends for their constant support and encouraging words. ii TABLE OF CONTENTS ACKNOWLEDGEMENTS…………………………………………………………....................ii LIST OF TABLES………………………………………………………………………………..iv LIST OF FIGURES……………………………………………………………………………….v LIST OF ABBREVIATIONS…………………………………………………………………….vi ABSTRACT…………………………………………………………………………………….viii CHAPTER 1. GENERAL INTRODUCTION……………………………………………………1 1.1 Nuclear Receptors……………………………………………………………………..1 1.2 Liver X Receptor……………………………………………………………………..12 1.3 14-3-3 Proteins……………………………………………………………………….18 1.4 Cell Lines…………………………………………………………………………….20 CHAPTER 2. MATERIALS AND METHODS………………………………………………...22 2.1 Cells and Expression Constructs………………………………………………..……22 2.2 Expression and Purification of Proteins…………………...…………………………23 2.3 In vitro Binding Assay……………………………………………………………….23 2.4 Transactivation Assays ……………………………………………………………...24 2.5 Electrophoretic Mobility Shift Assay ……………………………………………….24 2.6 Microscopy…………………………………………………………………………..25 2.7 Permeabilization Experiments……………………………………………………….26 CHAPTER 3. 14-3-3 INTERACTS WITH LIVER X RECEPTOR BUT NOT LIVER X RECEPTOR 3.1 Introduction…………………………………………………………………………..27 3.2 Results………………………………………………………………………………..29 3.3 Discussion……………………………………………………………………………34 CHAPTER 4.THE MECHANISM OF NUCLEAR EXPORT OF LIVER X RECEPTOR α AND LIVER X RECEPTOR β REQUIRES ENERGY AND IS CRM-1 INDPENDENT 4.1 Introduction…………………………………………………………………………..41 4.2 Results………………………………………………………………………………..41 4.3 Discussion……………………………………………………………………………42 REFERENCES…………………………………………………………………………………..45 APPENDIX. PERMISSIONS……………………………………………………………………57 VITA……………………………………………………………………………………………..83 iii LIST OF TABLES 1.1 Nuclear Receptor involvement in Physiology………………………………………………...2 1.2 A Proposed Nomenclature for Nuclear Receptors…………………………………………….8 1.3 LXR Target Genes and Their Function……………………………………………………...16 iv LIST OF FIGURES Figure 1.1 Human Nuclear Receptors Classes…………………………………………………….4 Figure 1.2 General structures of NRs……………………………………………………………10 Figure 1.3 Schematic of a Model for Directional Nucleocytoplasmic Transport Import or Export of Receptor-Cargo Complexes through Nuclear Pore Complex………………………………..11 Figure 1.4 The mechanism of transcriptional activity by LXRs…………………………………13 Figure 1.5 Liver X Receptor natural and synthetic ligands……………………………………...14 Figure 3.1 GST, GST 14-3-3ζ, GST-LXRα, and GST-LXRβ are being expressed in E.coli…...30 Figure 3.2 LXRβ but not LXRα interacts with 14-3-3 …………………………………………31 Figure 3.3 LXRα and LXRβ interact with RXR…………………………………………………31 Figure 3.4 LXRβ interacts with 14-3-3 ……………………………………………………...…32 Figure 3.5 Schematic presentations of C-terminal truncations of LXRβ………………………..32 Figure 3.6 155CFP-LXR but not 105CFP-LXR binds 14-3-3ζ………………………………34 Figure 3.7 14-3-3ζ does not affect LXRβ binding to DNA……………………………………...35 Figure 3.8 14-3-3ζ decreases the transcriptional activity of LXR ……………………………..36 Figure 3.9 PKA or PKC activators had no effect on the transcriptional activity of LXRβ with or without 14-3-3……………………………………………………………………………………37 Figure 3.10 14-3-3ζ did not affect the localization of LXR ……………………………………39 Figure 4.1 Nuclear export of LXRα requires energy but not Crm-1…………………………….43 Figure 4.2 Nuclear export of LXRβ requires energy but not Crm-1…………………………….44 v LIST OF ABBREVIATIONS NR- nuclear receptor DBD- DNA binding domain LBD- ligand binding domain LXR- liver x receptor NR1H2-nuclear receptor subfamily 1, group H, member 2 (LXRβ) NR1H3-nuclear receptor subfamily 1, group H, member 3 (LXRα) ABCA1- ATP binding cassette subfamily A member 1 SREBP-1C- sterol regulatory element binding protein 1C FAS- fatty acid synthase AR- androgen receptor ER- estrogen receptor GR- glucocorticoid receptor MR- mineralcorticoid receptor PR- progesterone receptor FXR- farnesoid X receptor PPAR- peroxisome proliferator-activated receptor RAR- retinoid receptor TR- thyroid hormone receptor VDR- vitamin D receptor Rev-erb- reverse oreientation c-erb ROR- retinoic acid receptor-related orphan receptor FOXO- forkhead box vi LDL- low density lipoproteins HDL- high density lipoproteins FDA-U.S. Food and Drug Administration HNF-4- hepatocyte nuclear factor 4 SF-1- steroidogenic factor SHP- small heterodimeric partner RIP140- receptor interacting protein 140 NCoR- nuclear receptor corepressor SMRT- silencing mediator of retinoic acid and thyroid hormone receptor PBS- phosphate buffer saline RCT- reverse cholesterol transport vii ABSTRACT Atherosclerosis is the leading cause of mortality in developed countries accounting for 50% of all deaths. Atherosclerosis develops when macrophages in the artery wall accumulate large amounts of cholesterol via uptake of oxidized low density lipoproteins (LDL), causing a negative effect on cholesterol metabolism. Thus, the development of atherosclerosis can be inhibited by increasing cholesterol efflux, which can be achieved by activating ATP binding cassette (ABC) transporters in macrophages. In particular, ABCA1 mediates reverse cholesterol transport to the liver via high density lipoproteins (HDL) and therefore is an attractive molecular target for raising HDL levels and protecting against atherosclerosis. ABCA1 gene expression is known to be regulated by various transcription factors, such as liver X receptor (LXR). LXRs are transcription factors that are activated via binding of ligands, which are oxysterols. Activated LXRs bind to promoter regions at specific sequences known as LXR response elements (LXRE) and regulate genes for cholesterol metabolism and transport, as well as for lipogenesis. Synthetic LXR ligands might be useful for treatment of atherosclerosis if they did not induce lipogenesis, which can lead to an accumulation of cholesterol via activation of steroid response element binding protein (SREBP)-1c in the liver. To develop selective treatments for atherosclerosis, we need to understand mechanisms of selective gene regulation. LXRs occur as two isotypes, LXRα (NR1H3) and LXRβ (NR1H2). Both isotypes regulate genes encoding proteins involved in cholesterol metabolism and transport, as well as in lipogenesis. However, knock-out studies have shown that LXRβ activation results in more effective gene activation in the periphery, such as in macrophages, which can promote cholesterol efflux. The mechanism of this LXR isotype- selectivity is poorly understood. In this document, we will show how protein-protein viii interactions affect LXR and LXR function and explore the mechanism of nuclear export of LXR and LXR . ix CHAPTER 1 GENERAL INTRODUCTION 1.1 Nuclear Receptors 1.1.1 Introduction Nuclear receptors are a large superfamily of transcription factors that regulate genes important to physiological functions such as homeostasis, reproduction, and development in target cells (Table 1.1). Nuclear receptor activity can be modified by binding to ligands, typically small biologically active compounds such as hormones and lipids. A few well known nuclear receptor ligands are hormones such as steroids, retinoids, thyroid hormone, and vitamin D3. A large number of nuclear receptors have been identified by amino acid sequence similarity to known receptors, but some have no identified natural ligand and are referred to as nuclear orphan receptors. Nuclear receptors are found within the cytoplasm and nucleus of the cell where they can directly regulate target genes by binding to a specific sequence on DNA, known as the response element, usually found within the promoter region of the target gene. Each response element consists of two half-sites of a consensus sequence which can be oriented as direct repeats or indirect repeats which allows nuclear receptors to bind as a monomer, homodimer, or heterodimer (Giguere 1999). The expression of a large number of genes is regulated by nuclear receptors. Many of these regulated genes are associated with major diseases such as cancer, diabetes, obesity, and atherosclerosis, which explain why nuclear
Recommended publications
  • Ligands of Therapeutic Utility for the Liver X Receptors
    molecules Review Ligands of Therapeutic Utility for the Liver X Receptors Rajesh Komati, Dominick Spadoni, Shilong Zheng, Jayalakshmi Sridhar, Kevin E. Riley and Guangdi Wang * Department of Chemistry and RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA; [email protected] (R.K.); [email protected] (D.S.); [email protected] (S.Z.); [email protected] (J.S.); [email protected] (K.E.R.) * Correspondence: [email protected] Academic Editor: Derek J. McPhee Received: 31 October 2016; Accepted: 30 December 2016; Published: 5 January 2017 Abstract: Liver X receptors (LXRs) have been increasingly recognized as a potential therapeutic target to treat pathological conditions ranging from vascular and metabolic diseases, neurological degeneration, to cancers that are driven by lipid metabolism. Amidst intensifying efforts to discover ligands that act through LXRs to achieve the sought-after pharmacological outcomes, several lead compounds are already being tested in clinical trials for a variety of disease interventions. While more potent and selective LXR ligands continue to emerge from screening of small molecule libraries, rational design, and empirical medicinal chemistry approaches, challenges remain in minimizing undesirable effects of LXR activation on lipid metabolism. This review provides a summary of known endogenous, naturally occurring, and synthetic ligands. The review also offers considerations from a molecular modeling perspective with which to design more specific LXRβ ligands based on the interaction energies of ligands and the important amino acid residues in the LXRβ ligand binding domain. Keywords: liver X receptors; LXRα; LXRβ specific ligands; atherosclerosis; diabetes; Alzheimer’s disease; cancer; lipid metabolism; molecular modeling; interaction energy 1.
    [Show full text]
  • The Anti-Inflammatory Role of Nuclear Receptors in Dendritic Cells
    The Anti-Inflammatory Role of Nuclear Receptors in Dendritic Cells A thesis submitted for the degree of Ph.D. By Mary Canavan B.Sc. (Hons), March 2012. Based on research carried out at School of Biotechnology, Dublin City University, Dublin 9, Ireland. Under the supervision of Dr. Christine Loscher. Declaration I hereby certify that this material, which I now submit for assessment on the programme of study leading to the award of Doctor of Philosophy is entirely my own work, that I have exercised reasonable care to ensure that the work is original, and does not to the best of my knowledge breach any law of copyright, and has not been taken from the work of others and to the extent that such work has been cited and acknowledged within the text of my work. Signed: ____________________ ID No.:__54351789__ Date: ______________ ACKNOWLEDGEMENTS There are so many people that I would like to thank and definitely not enough space to say exactly how grateful I am to you all. I have been lucky enough to work with an amazing group of people over the past few years. Firstly I would like to thank Christine for all your help, support, enthusiasm and patience – and for telling me not to do anymore of those p50 blots! I have thoroughly enjoyed working with you and learning from you over the last few years. To everyone in the Lab – you are the reason why I have such great memories when I look back at my time in DCU. Whenever I think of failed experiments, tough days and tears, there is always a great memory of you guys that goes along with it.
    [Show full text]
  • Liver X Receptor &Beta
    Cell Death and Differentiation (2014) 21, 1914–1924 & 2014 Macmillan Publishers Limited All rights reserved 1350-9047/14 www.nature.com/cdd Liver X receptor b activation induces pyroptosis of human and murine colon cancer cells V Derange`re1,2,3, A Chevriaux1,2, F Courtaut1,3, M Bruchard1,3, H Berger1,3, F Chalmin1,3, SZ Causse1, E Limagne1,3,FVe´gran1,3, S Ladoire1,2,3, B Simon4, W Boireau4, A Hichami1,3, L Apetoh1,2,3, G Mignot1, F Ghiringhelli1,2,3,5 and C Re´be´*,1,2,5 Liver X receptors (LXRs) have been proposed to have some anticancer properties, through molecular mechanisms that remain elusive. Here we report for the first time that LXR ligands induce caspase-1-dependent cell death of colon cancer cells. Caspase- 1 activation requires Nod-like-receptor pyrin domain containing 3 (NLRP3) inflammasome and ATP-mediated P2 Â 7 receptor activation. Surprisingly, LXRb is mainly located in the cytoplasm and has a non-genomic role by interacting with pannexin 1 leading to ATP secretion. Finally, LXR ligands have an antitumoral effect in a mouse colon cancer model, dependent on the presence of LXRb, pannexin 1, NLRP3 and caspase-1 within the tumor cells. Our results demonstrate that LXRb, through pannexin 1 interaction, can specifically induce caspase-1-dependent colon cancer cell death by pyroptosis. Cell Death and Differentiation (2014) 21, 1914–1924; doi:10.1038/cdd.2014.117; published online 15 August 2014 Liver X receptor a (LXRa) and b belong to the nuclear receptor However, a common feature of these reports is that all family.
    [Show full text]
  • Liver X Receptor Β Protects Dopaminergic Neurons in a Mouse Model of Parkinson Disease
    Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson disease Yu-bing Daia, Xin-jie Tana, Wan-fu Wua, Margaret Warnera, and Jan-Åke Gustafssona,b,1 aCenter for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX 77204; and bCenter for Biosciences, Department of Biosciences and Nutrition, Novum, 14186 Stockholm, Sweden Contributed by Jan-Åke Gustafsson, June 26, 2012 (sent for review April 13, 2012) Parkinson disease (PD) is a progressive neurodegenerative disease Liver X receptors (LXRα and LXRβ) are members of the nu- whose progression may be slowed, but at present there is no clear receptor superfamily of ligand-activated transcription factors. pharmacological intervention that would stop or reverse the These receptors are activated by naturally occurring oxysterols (14, disease. Liver X receptor β (LXRβ) is a member of the nuclear re- 15). There are two synthetic LXR agonists, T0901317 and GW3965. ceptor super gene family expressed in the central nervous system, T0901317 has been demonstrated to have agonistic effects on where it is important for cortical layering during development and receptors other than LXR, such as the Farnesoid X receptor and survival of dopaminergic neurons throughout life. In the present the Pregnane X receptor (16). However, GW3965 has an agonistic study we have used the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr- effect specifically on LXR. Activation of LXRs leads to release of idine (MPTP) model of PD to investigate the possible use of LXRβ associated corepressor proteins and interaction with coactivators, as a target for prevention or treatment of PD.
    [Show full text]
  • Cloud-Clone 16-17
    Cloud-Clone - 2016-17 Catalog Description Pack Size Supplier Rupee(RS) ACB028Hu CLIA Kit for Anti-Albumin Antibody (AAA) 96T Cloud-Clone 74750 AEA044Hu ELISA Kit for Anti-Growth Hormone Antibody (Anti-GHAb) 96T Cloud-Clone 74750 AEA255Hu ELISA Kit for Anti-Apolipoprotein Antibodies (AAHA) 96T Cloud-Clone 74750 AEA417Hu ELISA Kit for Anti-Proteolipid Protein 1, Myelin Antibody (Anti-PLP1) 96T Cloud-Clone 74750 AEA421Hu ELISA Kit for Anti-Myelin Oligodendrocyte Glycoprotein Antibody (Anti- 96T Cloud-Clone 74750 MOG) AEA465Hu ELISA Kit for Anti-Sperm Antibody (AsAb) 96T Cloud-Clone 74750 AEA539Hu ELISA Kit for Anti-Myelin Basic Protein Antibody (Anti-MBP) 96T Cloud-Clone 71250 AEA546Hu ELISA Kit for Anti-IgA Antibody 96T Cloud-Clone 71250 AEA601Hu ELISA Kit for Anti-Myeloperoxidase Antibody (Anti-MPO) 96T Cloud-Clone 71250 AEA747Hu ELISA Kit for Anti-Complement 1q Antibody (Anti-C1q) 96T Cloud-Clone 74750 AEA821Hu ELISA Kit for Anti-C Reactive Protein Antibody (Anti-CRP) 96T Cloud-Clone 74750 AEA895Hu ELISA Kit for Anti-Insulin Receptor Antibody (AIRA) 96T Cloud-Clone 74750 AEB028Hu ELISA Kit for Anti-Albumin Antibody (AAA) 96T Cloud-Clone 71250 AEB264Hu ELISA Kit for Insulin Autoantibody (IAA) 96T Cloud-Clone 74750 AEB480Hu ELISA Kit for Anti-Mannose Binding Lectin Antibody (Anti-MBL) 96T Cloud-Clone 88575 AED245Hu ELISA Kit for Anti-Glutamic Acid Decarboxylase Antibodies (Anti-GAD) 96T Cloud-Clone 71250 AEK505Hu ELISA Kit for Anti-Heparin/Platelet Factor 4 Antibodies (Anti-HPF4) 96T Cloud-Clone 71250 CCA005Hu CLIA Kit for Angiotensin II
    [Show full text]
  • 2 to Modulate Hepatic Lipolysis and Fatty Acid Metabolism
    Original article Bioenergetic cues shift FXR splicing towards FXRa2 to modulate hepatic lipolysis and fatty acid metabolism Jorge C. Correia 1,2, Julie Massart 3, Jan Freark de Boer 4, Margareta Porsmyr-Palmertz 1, Vicente Martínez-Redondo 1, Leandro Z. Agudelo 1, Indranil Sinha 5, David Meierhofer 6, Vera Ribeiro 2, Marie Björnholm 3, Sascha Sauer 6, Karin Dahlman-Wright 5, Juleen R. Zierath 3, Albert K. Groen 4, Jorge L. Ruas 1,* ABSTRACT Objective: Farnesoid X receptor (FXR) plays a prominent role in hepatic lipid metabolism. The FXR gene encodes four proteins with structural differences suggestive of discrete biological functions about which little is known. Methods: We expressed each FXR variant in primary hepatocytes and evaluated global gene expression, lipid profile, and metabolic fluxes. Gene À À delivery of FXR variants to Fxr / mouse liver was performed to evaluate their role in vivo. The effects of fasting and physical exercise on hepatic Fxr splicing were determined. Results: We show that FXR splice isoforms regulate largely different gene sets and have specific effects on hepatic metabolism. FXRa2 (but not a1) activates a broad transcriptional program in hepatocytes conducive to lipolysis, fatty acid oxidation, and ketogenesis. Consequently, FXRa2 À À decreases cellular lipid accumulation and improves cellular insulin signaling to AKT. FXRa2 expression in Fxr / mouse liver activates a similar gene program and robustly decreases hepatic triglyceride levels. On the other hand, FXRa1 reduces hepatic triglyceride content to a lesser extent and does so through regulation of lipogenic gene expression. Bioenergetic cues, such as fasting and exercise, dynamically regulate Fxr splicing in mouse liver to increase Fxra2 expression.
    [Show full text]
  • Regulation of Thyroid Hormone Activation Via the Liver X-Receptor/Retinoid X-Receptor Pathway
    179 Regulation of thyroid hormone activation via the liver X-receptor/retinoid X-receptor pathway Marcelo A Christoffolete*, Ma´rton Doleschall1,*, Pe´ter Egri1, Zsolt Liposits1, Ann Marie Zavacki2, Antonio C Bianco3 and Bala´zs Gereben1 Human and Natural Sciences Center, Federal University of ABC, Santo Andre-SP 09210-370, Brazil 1Laboratory of Endocrine Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Szigony u. 43, Budapest H-1083, Hungary 2Division of Endocrinology, Diabetes, and Hypertension, Thyroid Section, Brigham and Women’s Hospital, Boston, Massachusetts MA 02115, USA 3Division of Endocrinology, Diabetes and Metabolism, Miller School of Medicine, University of Miami, Miami, Florida FL 33136, USA (Correspondence should be addressed to B Gereben; Email: [email protected]) *(M A Christoffolete and M Doleschall contributed equally to this work) (M Doleschall is now at Inflammation Biology and Immungenomics Research Group, Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary) Abstract Thyroid hormone receptor (TR) and liver X-receptor (LXR) investigated if 9-cis retinoic acid (9-cis RA), the ligand for are the master regulators of lipid metabolism. Remarkably, a the heterodimeric partner of TR and LXR, RXR, could mouse with a targeted deletion of both LXRa and LXRb is regulate the hDIO2 promoter. Notably, 9-cis RA repressed resistant to western diet-induced obesity, and exhibits ectopic the hDIO2 luciferase reporter (1 mM, approximately four- liver expression of the thyroid hormone activating type 2 fold) in a dose-dependent manner, while coexpression of an deiodinase (D2). We hypothesized that LXR/retinoid inactive mutant RXR abolished this effect. However, it is X-receptor (RXR) signaling inhibits hepatic D2 expression, unlikely that RXR homodimers mediate the repression of and studied this using a luciferase reporter containing the hDIO2 since mutagenesis of a DR-1 at K506 bp did not human DIO2 (hDIO2) promoter in HepG2 cells.
    [Show full text]
  • (LXR/NR1H3) Regulates Differentiation of Hepatocyte-Like Cells Via
    Liver X receptor α (LXRα/NR1H3) regulates differentiation of hepatocyte-like cells via reciprocal regulation of HNF4α Kai-Ting Chen, Kelig Pernelle, Yuan-Hau Tsai, Yu-Hsuan Wu, Jui-Yu Hsieh, Ko-Hsun Liao, Christiane Guguen-Guillouzo, Hsei-Wei Wang To cite this version: Kai-Ting Chen, Kelig Pernelle, Yuan-Hau Tsai, Yu-Hsuan Wu, Jui-Yu Hsieh, et al.. Liver X recep- tor α (LXRα/NR1H3) regulates differentiation of hepatocyte-like cells via reciprocal regulation of HNF4α. Journal of Hepatology, Elsevier, 2014, 61 (6), pp.1276-1286. 10.1016/j.jhep.2014.07.025. hal-01072495 HAL Id: hal-01072495 https://hal.archives-ouvertes.fr/hal-01072495 Submitted on 8 Oct 2014 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. This is the author’s final draft post-refeering (post-print) Find more peer-reviewed articles on our open access repository: http://hal-univ-rennes1.archives-ouvertes.fr/ MANUSCRIPT ACCEPTED Liver X receptor a (LXRa/NR1H3) regulates differentiation of hepatocyte-like cells via reciprocal regulation of HNF4a Kai-Ting Chen1,2,3, Kelig Pernelle4, Yuan-Hau
    [Show full text]
  • Liver X-Receptors Alpha, Beta (Lxrs Α , Β) Level in Psoriasis
    Liver X-receptors alpha, beta (LXRs α , β) level in psoriasis Thesis Submitted for the fulfillment of Master Degree in Dermatology and Venereology BY Mohammad AbdAllah Ibrahim Awad (M.B., B.Ch., Faculty of Medicine, Cairo University) Supervisors Prof. Randa Mohammad Ahmad Youssef Professor of Dermatology, Faculty of Medicine Cairo University Prof. Laila Ahmed Rashed Professor of Biochemistry, Faculty of Medicine Cairo University Dr. Ghada Mohamed EL-hanafi Lecturer of Dermatology, Faculty of Medicine Cairo University Faculty of Medicine Cairo University 2011 ﺑﺴﻢ اﷲ اﻟﺮﺣﻤﻦ اﻟﺮﺣﻴﻢ "وﻣﺎ ﺗﻮﻓﻴﻘﻲ إﻻ ﺑﺎﷲ ﻋﻠﻴﻪ ﺗﻮآﻠﺖ وإﻟﻴﻪ أﻧﻴﺐ" (هﻮد، ٨٨) Acknowledgement Acknowledgement First and foremost, I am thankful to God, for without his grace, this work would never have been accomplished. I am honored to have Prof.Dr. Randa Mohammad Ahmad Youssef, Professor of Dermatology, Faculty of Medicine, Cairo University, as a supervisor of this work. I am so grateful and most appreciative to her efforts. No words can express what I owe her for hers endless patience and continuous advice and support. My sincere appreciation goes to Dr. Ghada Mohamed EL-hanafi, Lecturer of Dermatology, Faculty of Medicine, Cairo University, for her advice, support and supervision during the course of this study. I am deeply thankful to Dr. Laila Ahmed Rashed, Assistant professor of biochemistry, Faculty of Medicine, Cairo University, for her immense help, continuous support and encouragement. Furthermore, I wish to express my thanks to all my professors, my senior staff members, my wonderful friends and colleagues for their guidance and cooperation throughout the conduction of this work. Finally, I would like to thank my father who was very supportive and encouraging.
    [Show full text]
  • Chain Hydroxycholesterols in Triple Negative Breast Cancer
    Oncogene (2021) 40:2872–2883 https://doi.org/10.1038/s41388-021-01720-w ARTICLE Liver x receptor alpha drives chemoresistance in response to side- chain hydroxycholesterols in triple negative breast cancer 1,2 1 1 3 1 Samantha A. Hutchinson ● Alex Websdale ● Giorgia Cioccoloni ● Hanne Røberg-Larsen ● Priscilia Lianto ● 4 5 1 5 4 4 Baek Kim ● Ailsa Rose ● Chrysa Soteriou ● Arindam Pramanik ● Laura M. Wastall ● Bethany J. Williams ● 6 6 6 1 6,7,8,9,10 Madeline A. Henn ● Joy J. Chen ● Liqian Ma ● J. Bernadette Moore ● Erik Nelson ● 5,11 1,11 Thomas A. Hughes ● James L. Thorne Received: 6 August 2020 / Revised: 15 February 2021 / Accepted: 18 February 2021 / Published online: 19 March 2021 © The Author(s) 2021. This article is published with open access Abstract Triple negative breast cancer (TNBC) is challenging to treat successfully because targeted therapies do not exist. Instead, systemic therapy is typically restricted to cytotoxic chemotherapy, which fails more often in patients with elevated circulating cholesterol. Liver x receptors are ligand-dependent transcription factors that are homeostatic regulators of cholesterol, and are linked to regulation of broad-affinity xenobiotic transporter activity in non-tumor tissues. We show that 1234567890();,: 1234567890();,: LXR ligands confer chemotherapy resistance in TNBC cell lines and xenografts, and that LXRalpha is necessary and sufficient to mediate this resistance. Furthermore, in TNBC patients who had cancer recurrences, LXRalpha and ligands were independent markers of poor prognosis and correlated with P-glycoprotein expression. However, in patients who survived their disease, LXRalpha signaling and P-glycoprotein were decoupled. These data reveal a novel chemotherapy resistance mechanism in this poor prognosis subtype of breast cancer.
    [Show full text]
  • Multifaceted Control of GR Signaling and Its Impact on Hepatic Transcriptional Networks and Metabolism
    University of Southern Denmark Multifaceted Control of GR Signaling and Its Impact on Hepatic Transcriptional Networks and Metabolism Præstholm, Stine M.; Correia, Catarina M.; Grøntved, Lars Published in: Frontiers in Endocrinology DOI: 10.3389/fendo.2020.572981 Publication date: 2020 Document version: Final published version Document license: CC BY Citation for pulished version (APA): Præstholm, S. M., Correia, C. M., & Grøntved, L. (2020). Multifaceted Control of GR Signaling and Its Impact on Hepatic Transcriptional Networks and Metabolism. Frontiers in Endocrinology, 11, [572981]. https://doi.org/10.3389/fendo.2020.572981 Go to publication entry in University of Southern Denmark's Research Portal Terms of use This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply: • You may download this work for personal use only. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying this open access version If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to [email protected] Download date: 29. Sep. 2021 REVIEW published: 08 October 2020 doi: 10.3389/fendo.2020.572981 Multifaceted Control of GR Signaling and Its Impact on Hepatic Transcriptional Networks and Metabolism Stine M. Præstholm †, Catarina M. Correia † and Lars Grøntved* Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark Glucocorticoids (GCs) and the glucocorticoid receptor (GR) are important regulators of development, inflammation, stress response and metabolism, demonstrated in various diseases including Addison’s disease, Cushing’s syndrome and by the many side effects of prolonged clinical administration of GCs.
    [Show full text]
  • Liver X Receptors: a Possible Link Between Lipid Disorders and Female Infertility
    International Journal of Molecular Sciences Review Liver X Receptors: A Possible Link between Lipid Disorders and Female Infertility Sarah Dallel 1,2,3, Igor Tauveron 1,3, Florence Brugnon 4,5, Silvère Baron 1,2,*, Jean Marc A. Lobaccaro 1,2,* ID and Salwan Maqdasy 1,2,3 1 Université Clermont Auvergne, GReD, CNRS UMR 6293, INSERM U1103, 28, Place Henri Dunant, BP38, F63001 Clermont-Ferrand, France; [email protected] (S.D.); [email protected] (I.T.); [email protected] (S.M.) 2 Centre de Recherche en Nutrition Humaine d’Auvergne, 58 Boulevard Montalembert, F-63009 Clermont-Ferrand, France 3 Service d’Endocrinologie, Diabétologie et Maladies Métaboliques, CHU Clermont Ferrand, Hôpital Gabriel Montpied, F-63003 Clermont-Ferrand, France 4 Université Clermont Auvergne, ImoST, INSERM U1240, 58, rue Montalembert, BP184, F63005 Clermont-Ferrand, France; [email protected] 5 CHU Clermont Ferrand, Assistance Médicale à la Procréation-CECOS, Hôpital Estaing, Place Lucie et Raymond Aubrac, F-63003 Clermont-Ferrand CEDEX 1, France * Correspondence: [email protected] (S.B.); [email protected] (J.M.A.L.); Tel.: +33-473-407-412 (S.B.); +33-473-407-416 (J.M.A.L.) Received: 6 July 2018; Accepted: 19 July 2018; Published: 25 July 2018 Abstract: A close relationship exists between cholesterol and female reproductive physiology. Indeed, cholesterol is crucial for steroid synthesis by ovary and placenta, and primordial for cell structure during folliculogenesis. Furthermore, oxysterols, cholesterol-derived ligands, play a potential role in oocyte maturation. Anomalies of cholesterol metabolism are frequently linked to infertility. However, little is known about the molecular mechanisms.
    [Show full text]